TolaSure is a topical gel for the promotion of accelerated wound healing. This Phase I study will assess the safety, tolerability, and clinical effects of TolaSure when applied to wounded skin areas of patients diagnosed with severe epidermolysis bullosa simplex (i.e., EBS-Dowling Meara). A total of 10, severe EBS patients, males and females ages 18 years and older, will be enrolled. Patients will apply TolaSure and Vehicle Gel once-daily for a maximum of 10 weeks.
All costs, including travel, lodging, transportation, and food will be covered, and the participants will also receive a stipend for each in-person visit.
- Patient is a male or female at least 18 years of age.
- Patient has a documented genetic mutation in either the keratin 14 (K14) or keratin 5 (K5) gene and that their EBS diagnosis and/or specific mutation are consistent with severe EBS (previously EBS-DM). (If severe EBS is suspected but not genetically confirmed, confirmatory testing will be performed).
- Please click the link below for more inclusion and exclusion criteria.
If you have any questions or are interested in participating in this clinical trial, please contact:
- Irene Bailey
- Phone: 650-721-7149
- Email: baileyhi@stanford.edu
Location:
Stanford University School of Medicine, Dermatology Department
Redwood City, California, United States, 94063
